JP2019172710A5 - - Google Patents

Download PDF

Info

Publication number
JP2019172710A5
JP2019172710A5 JP2019132496A JP2019132496A JP2019172710A5 JP 2019172710 A5 JP2019172710 A5 JP 2019172710A5 JP 2019132496 A JP2019132496 A JP 2019132496A JP 2019132496 A JP2019132496 A JP 2019132496A JP 2019172710 A5 JP2019172710 A5 JP 2019172710A5
Authority
JP
Japan
Prior art keywords
lys
gly
conjugate
phe
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019132496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019172710A (ja
JP6908656B2 (ja
Filing date
Publication date
Priority claimed from JP2016542987A external-priority patent/JP6560681B2/ja
Application filed filed Critical
Publication of JP2019172710A publication Critical patent/JP2019172710A/ja
Publication of JP2019172710A5 publication Critical patent/JP2019172710A5/ja
Application granted granted Critical
Publication of JP6908656B2 publication Critical patent/JP6908656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019132496A 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系 Active JP6908656B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921242P 2013-12-27 2013-12-27
US61/921,242 2013-12-27
US201462051899P 2014-09-17 2014-09-17
US62/051,899 2014-09-17
JP2016542987A JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016542987A Division JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系

Publications (3)

Publication Number Publication Date
JP2019172710A JP2019172710A (ja) 2019-10-10
JP2019172710A5 true JP2019172710A5 (enExample) 2020-01-23
JP6908656B2 JP6908656B2 (ja) 2021-07-28

Family

ID=53477242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016542987A Active JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系
JP2019132496A Active JP6908656B2 (ja) 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016542987A Active JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系

Country Status (14)

Country Link
US (2) US11560422B2 (enExample)
EP (1) EP3086815B1 (enExample)
JP (2) JP6560681B2 (enExample)
KR (1) KR102384740B1 (enExample)
CN (1) CN106255513B (enExample)
AU (1) AU2014373574B2 (enExample)
CA (1) CA2935077C (enExample)
DK (1) DK3086815T3 (enExample)
ES (1) ES2916722T3 (enExample)
IL (1) IL246457B (enExample)
MX (1) MX384608B (enExample)
PL (1) PL3086815T3 (enExample)
RU (1) RU2729194C2 (enExample)
WO (1) WO2015095953A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
DK3086815T3 (da) 2013-12-27 2022-05-23 Zymeworks Inc Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Var2csa-약물 접합체
RU2723651C2 (ru) 2014-09-17 2020-06-17 Займворкс Инк. Цитотоксические и антимитотические соединения и способы их применения
WO2016053107A1 (en) 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11951175B2 (en) * 2016-02-08 2024-04-09 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
WO2017137423A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Improved sulfamide linkers for use in bioconjugates
US11338043B2 (en) * 2016-02-08 2022-05-24 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates
CR20180452A (es) 2016-03-22 2019-02-06 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotícos
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JP7202301B2 (ja) 2017-08-10 2023-01-11 住友ファーマ株式会社 ヘミアスタリン誘導体及びこれらの抗体薬物複合体
PT3666787T (pt) 2017-08-10 2024-03-21 Sumitomo Pharma Co Ltd Conjugados anticorpo-fármaco que incluem um derivado da hemiasterlina
IL277049B2 (en) * 2018-03-13 2024-02-01 Zymeworks Bc Inc Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
IL278973B2 (en) * 2018-05-29 2025-07-01 Intocell Inc History of new benzodiazepines and their uses
CA3118026A1 (en) 2018-10-31 2020-05-07 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
MX2021005484A (es) 2018-11-09 2021-06-18 Byondis Bv Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados.
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
WO2020166600A1 (ja) 2019-02-13 2020-08-20 大日本住友製薬株式会社 システイン残基を有するヘミアスタリン誘導体
CN113024405A (zh) * 2019-12-25 2021-06-25 上海奥博生物医药技术有限公司 一种新的拉考沙胺杂质及其制备方法和用途
CA3170633A1 (en) * 2020-03-09 2021-09-16 David Goeddel Efficient preparation of dolastatin and auristatin analogs through a common intermediate
IL319125A (en) 2022-08-22 2025-04-01 Abdera Therapeutics Inc DLL3 binding molecules and their uses

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
CA1213229A (en) 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5094849A (en) 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
PL178766B1 (pl) 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2173150C (en) 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
EP0867190B1 (en) 1995-05-10 2007-12-26 Kyowa Hakko Kogyo Co., Ltd. Cytotoxin complexes comprising dipeptides
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
EP1149843A4 (en) 1999-01-28 2012-06-06 Chugai Pharmaceutical Co Ltd SUBSTITUTED PHENETHYLAMINE DERIVATIVES
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
AU2001275525B2 (en) 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
TWI245034B (en) 2000-07-24 2005-12-11 Matsushita Electric Industrial Co Ltd Capacitor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP1531846A4 (en) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7192972B2 (en) 2002-03-22 2007-03-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US7211696B2 (en) 2002-04-23 2007-05-01 The Ohio State University Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
CN1705639A (zh) 2002-09-20 2005-12-07 惠氏控股公司 用于合成微管蛋白抑制剂的中间体的合成方法
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
AU2003295808A1 (en) 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
US7390910B2 (en) 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1670800A1 (en) 2003-09-15 2006-06-21 The University of British Columbia Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof
US8007782B2 (en) 2003-10-22 2011-08-30 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US7078562B2 (en) 2004-01-19 2006-07-18 Mitsubishi Gas Chemical Company, Inc. Adamantane derivatives and resin compositions using the same as raw material
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
KR20070053214A (ko) 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
CN101039701A (zh) * 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
US20090130136A1 (en) 2004-09-30 2009-05-21 Miller Louis H Chondroitin Sulphate a Binding Domains
EP3505191A1 (en) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
WO2006065533A2 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
EP1827603A2 (en) 2004-12-13 2007-09-05 F. Hoffmann-Roche AG Novel pharmaceutical composition containing at least one dolastatin 10 derivative
CA2589773A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
CA2617907A1 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
EP1940470B1 (en) 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
WO2009134279A1 (en) 2007-07-20 2009-11-05 The Regents Of The University Of California Tubulysin d analogues
AU2008309589B2 (en) 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
WO2009059309A2 (en) 2007-11-01 2009-05-07 Panacea Pharmaceuticals, Inc. Furin-cleavable peptide linkers for drug-ligand conjugates
BRPI0905752B1 (pt) 2008-01-30 2021-11-23 Pieris Ag Muteína de lipocalina da lágrima humana (htlc), composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana e uso in vitro de uma muteína de lipocalina da lágrima humana
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
ES2536882T3 (es) 2008-07-21 2015-05-29 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
CN102292102A (zh) 2008-11-21 2011-12-21 哥本哈根大学 免疫应答的引发
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
KR20120057588A (ko) 2009-05-28 2012-06-05 메르사나 테라퓨틱스, 인코포레이티드 가변 속도 방출 링커를 포함하는 폴리알 약물 접합체
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
BR112012008159A2 (pt) 2009-08-28 2016-03-01 Arena Pharm Inc moduladores de receptor canabinoide
RU2563639C2 (ru) 2009-09-25 2015-09-20 Астеллас Фарма Инк. Замещенные соединения амида
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CN103200950B (zh) 2010-06-10 2016-03-16 西雅图基因公司 新颖的耳他汀衍生物及其用途
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DK2678037T3 (en) 2011-02-25 2015-03-09 Lonza Ag Branched linker for protein pharmaceutical conjugates
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012123957A1 (en) 2011-03-16 2012-09-20 Council Of Scientific & Industrial Research Oligopeptides and process for preparation thereof
JP6023097B2 (ja) 2011-03-16 2016-11-09 シアトル ジェネティックス, インコーポレイテッド Nカルボキシアルキルオーリスタチンおよびその使用
EP2690955A4 (en) 2011-03-30 2014-10-15 Univ Arizona AURISTATINE TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOCHINOLINE DERIVATIVES AND PRODRUGS THEREOF
AU2012244673A1 (en) 2011-04-21 2013-11-28 Seattle Genetics, Inc. Novel binder-drug conjugates (ADCs) and their use
KR102179369B1 (ko) 2011-05-27 2020-11-16 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
EP2714685B1 (en) 2011-05-27 2016-10-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
EP3228325A1 (en) 2011-06-10 2017-10-11 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US20130190248A1 (en) 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
EP2776409B1 (en) 2011-11-09 2016-02-03 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CN104185477B (zh) 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
MX2014006739A (es) 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
US9061000B2 (en) 2012-01-19 2015-06-23 Chao-Han LAI Pharmacological treatment of aortic aneurysm development
ES2676029T3 (es) 2012-02-09 2018-07-16 Var2 Pharmaceuticals Aps Direccionamiento de glicanos de sulfato de condroitina
HK1208216A1 (en) * 2012-05-15 2016-02-26 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
KR102143664B1 (ko) 2012-06-07 2020-08-11 암브룩스, 인코포레이티드 전립선 특이적 막 항원 항체 약물 접합체
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
HUE048574T2 (hu) 2012-07-12 2020-08-28 Hangzhou Dac Biotech Co Ltd Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai
TW201428002A (zh) 2012-11-09 2014-07-16 必治妥美雅史谷比公司 用於抑制細胞凋亡抑制劑之巨環化合物
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
EP2740491A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
AR094280A1 (es) 2012-12-21 2015-07-22 Bioalliance Cv Enlazantes hidrofilicos auto-inmolantes y conjugados de los mismos
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
KR20150119206A (ko) 2013-02-15 2015-10-23 가부시키가이샤 페르세우스 프로테오믹스 항 cdh3 인간화 항체, 그의 약물 콘쥬게이트, 이들의 용도
AU2014228489B2 (en) * 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US9988420B2 (en) 2013-12-17 2018-06-05 Novartis Ag Cytotoxic peptides and conjugates thereof
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Var2csa-약물 접합체
DK3086815T3 (da) 2013-12-27 2022-05-23 Zymeworks Inc Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater
RU2723651C2 (ru) 2014-09-17 2020-06-17 Займворкс Инк. Цитотоксические и антимитотические соединения и способы их применения
WO2016123412A1 (en) 2015-01-28 2016-08-04 Sorrento Therapeutics, Inc. Antibody drug conjugates
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules

Similar Documents

Publication Publication Date Title
JP2019172710A5 (enExample)
JP2022046569A5 (enExample)
Maderna et al. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates
JP2022043354A (ja) 改善されたリガンド-薬物コンジュゲート薬物動態のためのpeg化薬物-リンカー
TW202010498A (zh) 喜樹鹼肽結合物
US20200317612A1 (en) Branched Discrete PEG Constructs
JP3607201B2 (ja) Fap活性化抗腫瘍性化合物
IL323631A (en) Compositions containing, methods and uses of antibody-TLR agonist conjugates
JP2020063241A5 (enExample)
JP2018504925A5 (enExample)
JP2017537893A5 (enExample)
JP7814303B2 (ja) 内部移行した生物学的に活性な化合物の結合体からの選択的な薬物放出
JP2016508136A5 (enExample)
JP2017502047A5 (enExample)
JP2019500327A5 (enExample)
CA3148621A1 (en) Compositions and methods comprising protease-activated therapeutic agents
JP2018510864A (ja) トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
JP2017160222A5 (enExample)
IL297859A (en) Antibody-drug conjugates comprising sting agonists
CN1649614A (zh) 活性剂传递系统和保护及施用活性剂的方法
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JP2015524796A5 (ja) 細胞毒性剤と細胞結合受容体との共役体
EA038512B1 (ru) Конъюгаты майтанзиноидов и их терапевтическое применение
JP2019043957A5 (enExample)
RU2015129800A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты